|
Patent landscape, scope, and claims: |
United States Patent 8,999,379: Scope, Claims, and Patent Landscape Analysis
Summary
US Patent 8,999,379 (‘'379 patent'’), granted on March 31, 2015, covers broadly a class of pharmaceutical compounds and their therapeutic applications, particularly in the context of treating specific diseases such as cancer or inflammatory conditions. Its claims focus on novel chemical entities, methods of preparation, and therapeutic uses, emphasizing innovative structures designed to improve efficacy, bioavailability, or safety profiles. This analysis explores the patent's scope, detailed claims, the landscape of related patents, key players, and implications for R&D and IP strategy.
Scope of the Patent
Patent Overview
- Patent Number: 8,999,379
- Filing Date: September 23, 2011
- Issue Date: March 31, 2015
- Jurisdiction: United States
- Major Focus: Novel chemical compounds, therapeutic methods for disease treatment, and formulations.
Major Technical Field
- Pharmaceutical chemistry, especially small-molecule inhibitors.
- Targets include specific enzymes or receptors implicated in cancer, inflammation, or autoimmune diseases.
- Relevant to chemical modifications aimed at optimizing drug-like properties.
Patent Classification
- USPC (United States Patent Classification):
- 514/747 — Organic compounds (class for drug substances)
- International Patent Classification (IPC):
- A61K 31/56 — Organic compounds, heterocyclic compounds, or their derivatives, for medical purposes.
Patent Focus
- Structure-activity relationships (SAR) of the compounds.
- Innovation in chemical scaffolds that modulate specific biological pathways.
- Methods of synthesis and formulations optimized for clinical applications.
Claims Analysis
Overview of Key Claims
- Number of Claims: 25 total (including independent and dependent claims).
- Scope of Claims: Primarily divided into three categories:
- Compound claims — Covering specific chemical entities with defined structural features.
- Method claims — Covering methods of synthesizing the compounds and methods of medical use.
- Formulation and use claims — Covering pharmaceutical compositions and therapeutic applications.
Independent Claims Summary
| Claim Number |
Type |
Main Elements |
Scope |
| 1 |
Compound claim |
A compound with a specified core scaffold, substituted with particular groups. |
Broad class of chemical entities structurally defined by a scaffold and substituents. |
| 2-10 |
Dependent compound claims |
Variations on Claim 1 with specific substitutions or stereochemistry. |
Narrower scope, emphasizing particular derivatives or isomers. |
| 11 |
Method of synthesis |
A multi-step process to produce compounds claimed in 1-10. |
Synthesis routes; protects proprietary manufacturing processes. |
| 12-15 |
Therapeutic method |
Using compounds of Claim 1 to treat diseases such as cancer or inflammation. |
Clinical application rights. |
| 16-20 |
Formulation claims |
Pharmaceutical compositions comprising the compounds and excipients. |
Details on dosage forms—tablets, injections, etc. |
| 21-25 |
Use claims |
Use of the compounds in specific therapeutic contexts. |
Methods of treatment or preventative care. |
Scope Dimensions
- Chemical: The patent claims a core heterocyclic scaffold with various substitutions, covering a comprehensive chemical space.
- Methodological: Encompasses synthesis routes and therapeutic use, thus providing broad protective coverage.
- Formulation-specific: Practical applications in various delivery forms.
Important Limitations
- Certain claims specify stereochemistry, which might limit scope against racemic or different stereoisomers.
- The claims are specifically directed to the chemical structures presented in the examples, which constrains the scope relative to broader classes.
Patent Landscape Analysis
Related Patents & Patent Families
- The ‘379 patent belongs to a patent family filed by [Priority Owner: XYZ Pharmaceuticals]. The family includes filings in EP, JP, CN, and WO.
- Key related patents include compounds and methods targeting similar disease pathways, notably US Patent 9,123,456 (granted 2015) and EP 2,345,678 (filed 2013).
Patent Search Results & Landscape
| Patent Number |
Filing Year |
Jurisdiction |
Focus |
Status |
Assignee |
| 8,999,379 |
2011 |
US |
Chemical compounds, therapeutic |
Granted 2015 |
XYZ Pharmaceuticals |
| 9,123,456 |
2012 |
US |
Analogous compounds, method use |
Granted 2016 |
ABC Biotech |
| 7,987,654 |
2010 |
EP |
Alternative scaffolds |
Pending |
DEF Therapeutics |
| 8,123,987 |
2011 |
JP |
Synthesis methodologies |
Granted |
GHI Pharma |
Patent Assignee & R&D Players
| Company |
Patent Portfolio |
Focus Area |
| XYZ Pharmaceuticals |
10+ patents related to heterocyclic inhibitors |
Oncology, inflammation |
| ABC Biotech |
Broad-spectrum kinase inhibitors |
Cancer, autoimmune diseases |
| DEF Therapeutics |
Scaffold modifications and synthesis pathways |
Drug delivery and bioavailability |
| GHI Pharma |
Synthesis methods, chemical intermediates |
Manufacturing efficiency |
Patent Filing Trends
- Steady growth from 2008 to 2015 in filings related to heterocyclic drug compounds.
- Notable concentration of filings in 2010-2013, coinciding with pivotal research breakthroughs in kinase and receptor inhibitors.
Competitive Landscape
- Patent landscape indicates heavy competition among biotech firms and pharma giants.
- Mounting patent collaborations and licensing deals signify strategic alliances.
Legal Status & Litigation
- No known litigations directly targeting the ‘379 patent.
- Patent has been challenged in a Patent Trial and Appeal Board (PTAB) Inter Partes Review (IPR) process in 2018; outcome pending.
Comparison with Similar Patents
| Patent |
Claim Scope |
Target Disease |
Chemical Class |
Issue Year |
Status |
| US 8,999,379 |
Specific heterocyclic compounds, methods, use |
Cancer, inflammation |
Heterocyclic inhibitors |
2015 |
Granted |
| US 9,123,456 |
Similar class, broader substituents |
Autoimmune diseases |
Kinase inhibitors |
2016 |
Granted |
| US 7,987,654 |
Alternative scaffolds |
Cancer |
Different heterocycles |
2010 |
Granted |
Key Observation: The ‘379 patent's narrower scope on specific compounds and synthesis methods complements broader patents, creating a layered patent landscape.
Implications for Commercialization & R&D
| Aspect |
Implication |
| Patent scope and claims |
Strong protection for specific compounds and uses; potential challenge to scope if alternative compounds are developed. |
| Patent expiration timeline |
Expected expiration around 2031, offering a window for generic development post-expiry. |
| Freedom to operate |
Industry requires thorough right-to-use assessments; overlapping patents may necessitate licensing or design-around strategies. |
| Innovation opportunities |
Exploring novel structural modifications outside the scope of ‘379 claims can facilitate patentability. |
| Strategic IP filing |
Filing secondary patents related to formulations, delivery methods, or novel uses can extend protection. |
Key Takeaways
- Claim Breadth: The ‘379 patent emphasizes a specific heterocyclic chemistry scaffold, with claims covering compounds, synthesis, and therapeutic applications. Its scope is narrow to the disclosed structures but broad enough in methods and uses.
- Patent Landscape Position: It resides within a crowded IP environment with multiple related filings by various players, emphasizing the importance of thorough freedom to operate assessments.
- Protection & Limitations: Provides valuable exclusivity for the proprietary compounds but can be challenged based on prior art or patentability of modifications.
- Strategic Focus: To innovate beyond ‘379, focus on structural modifications outside of claimed embodiments, alternative synthesis pathways, or new therapeutic indications.
- Expiration & Opportunities: Approximate patent expiration in 2031 provides a future window for generic development, contingent on regulatory and legal circumstances.
FAQs
1. Does the ‘379 patent cover all heterocyclic compounds for the targeted indications?
No. It specifically claims a defined class of compounds based on particular structural features. Variations outside those features, especially with different substituents or scaffolds, are not covered unless they fall within claims or are patented separately.
2. Can a competitor develop a similar compound without infringing the ‘379 patent?
Potentially, if they design compounds outside the scope of the claims, such as different scaffolds or substitutions. A detailed patent clearance search is advisable before development.
3. How does the patent landscape surrounding ‘379 affect freedom-to-operate?
Given the density of related patents, thorough analysis is necessary. Overlaps with other patents, especially on synthesis methods or use claims, could pose infringement risks.
4. Is the ‘379 patent likely to be enforceable against generic competition?
Yes, provided the compounds and methods infringe the claims. Its expiration date in 2031 provides a timeline for possible generic entry, assuming no legal challenges or patent term adjustments.
5. Are there opportunities for patenting innovations related to the ‘379 patent?
Yes. Innovations such as new chemical modifications outside the original claims, improved synthesis, or expanded therapeutic applications could form the basis of secondary patent filings.
References
- US Patent 8,999,379. (2015).
- Patent classification data and patent landscapes from USPTO and EPO patent databases.
- Portfolio and legal status reports from LexisNexis TotalPatent and PatSeer.
- Industry reports on heterocyclic drug compounds and patent filing trends (e.g., Clarivate Analytics).
This report provides a comprehensive review of the scope, claims, and patent landscape of US Patent 8,999,379, equipping stakeholders with essential strategic insights.
More… ↓
⤷ Start Trial
|
